Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and M032 in Malignant Glioma
NCT05084430Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2022
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of M032 in glioblastoma multiforme (GBM), astrocytoma, Gliosarcoma (GS), sponsored by University of Alabama at Birmingham. Started Feb 2022; status: recruiting.
02
Drugs
M032
03
Conditions
glioblastoma multiforme (GBM)astrocytomaGliosarcoma (GS)
Beyond the preview
Go deeper on NCT05084430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084430.